When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?  

I generally offer tarlatamab as a second line option in small cell lung cancer patients who are fit (ECOG 0-1), can logistically accommodate the hospitalization and infusion schedule, have low-risk factors for ICANS, and have treated brain metastases. I would consider a platinum etoposide rechalleng...

I have used lurbinectedin as my second line. As tarlatamab was studied in patients who had 2 or more prior lines of therapy in the DeLLphi-301 study, I have started using it as my preferred third line treatment.